Research development of HER2 in gastric and gastroesophageal junction adenocarcinoma
10.3760/cma.j.issn.1673-4203.2013.07.014
- VernacularTitle:胃及胃食道交界处癌中HER2研究进展
- Author:
Cheng CAO
;
Xiangling MENG
- Publication Type:Journal Article
- Keywords:
Stomach neoplasms;
Carcinoma;
Gastroesophageal junction adenocarcinomas;
Human epidermal growth factor receptor 2;
Molecular targeted therapy
- From:
International Journal of Surgery
2013;40(7):475-478
- CountryChina
- Language:Chinese
-
Abstract:
Amplification of the human epidermal growth factor receptor 2/neu (HER2/neu) gene and overexpression of the HER2 protein (HER2) have been shown to occur in gastric and gastroesophageal junction adenocarcinoma in a number of studies.With a dismal survival rate,patients with these cancers stand to benefit from the identification of possible molecular targets such as HER2 for both prognostic and therapeutic purposes.Although these and other carcinomas that overexpress HER2 may have a poorer prognosis and exhibit resistance to conventional chemo-therapy,they have also recently been shown to respond to targeted therapy with the anti-HER2 antibody Trastuzumab.Here,the author briefly review the molecular biology,histopathology,diagnostic techniques,and interpretation,as well as the clinical implications of HER2 amplification/overexpression in gastric and gastroesophageal adenocarcinoma.
